Eisai drugs

Eisai serves as the lead in the co-development of lecanemab. 3. About the Collaboration between Eisai and BioArctic for Alzheimer s Disease; Since 2024, BioArctic has had a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of AD.

drug, aducanumab, developed by Japanese and American companies Eisai and Biogen, and found it to be rife with irregularities. The

On, Eisai and UCL signed a 2-year extension of the Drug Discovery and Development Collaboration Agreement to identify

organizations such as the Drugs for Neglected Diseases initiative (DNDi) and Sabin Vaccine Institute as Medicines page on the Eisai global

Eisai new US headquarters. Eisai and Biogen's drug nabbed an FDA approval at the start of the year, but making good on its blockbuster sales

-epileptic drugs include UCB's Keppra and Vimpat, GSK's Lamictal, and Eisai's Banzel, Zonegran, and Fycompa.

Eisai's news release EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS

The Food and Drug Administration has approved lecanemab, a drug developed by Eisai and Biogen with the goal of slowing the progression of

Eisai's news release EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN